Sébastien Briolant

Author PubWeight™ 37.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J 2011 1.63
2 Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother 2009 1.59
3 Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother 2007 1.33
4 Molecular detection of Bartonella quintana, B. Elizabethae, B. Koehlerae, B. Doshiae, B. Taylorii, and Rickettsia felis in rodent fleas collected in Kabul, Afghanistan. Am J Trop Med Hyg 2006 1.24
5 Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. Malar J 2013 1.23
6 The use of remotely sensed environmental data in the study of malaria. Geospat Health 2011 1.22
7 Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. J Antimicrob Chemother 2011 1.19
8 In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother 2011 1.10
9 Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009 1.10
10 Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg 2011 1.10
11 Antimalarial drug use in general populations of tropical Africa. Malar J 2008 1.09
12 In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2008 1.06
13 Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J 2012 1.06
14 PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. Malar J 2013 1.05
15 Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malar J 2010 1.05
16 Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. J Antimicrob Chemother 2010 1.04
17 Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J 2013 0.96
18 Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J 2015 0.95
19 High prevalence and fixation of Plasmodium vivax dhfr/dhps mutations related to sulfadoxine/pyrimethamine resistance in French Guiana. Am J Trop Med Hyg 2009 0.94
20 Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin. Antimicrob Agents Chemother 2012 0.92
21 Mosquito magnet® liberty plus trap baited with octenol confirmed best candidate for Anopheles surveillance and proved promising in predicting risk of malaria transmission in French Guiana. Malar J 2014 0.92
22 Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. Malar J 2013 0.92
23 Differential association of Plasmodium falciparum Na+/H+ exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum. Antimicrob Agents Chemother 2011 0.91
24 Malaria in French Guiana Linked to Illegal Gold Mining. Emerg Infect Dis 2016 0.91
25 Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. Malar J 2010 0.91
26 Efficacy of proveblue (methylene blue) in an experimental cerebral malaria murine model. Antimicrob Agents Chemother 2013 0.90
27 Population genetics analysis during the elimination process of Plasmodium falciparum in Djibouti. Malar J 2013 0.90
28 Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Antimicrob Agents Chemother 2009 0.90
29 Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Malar J 2012 0.90
30 Plasmodium vivax and Plasmodium falciparum infections in the Republic of Djibouti: evaluation of their prevalence and potential determinants. Malar J 2012 0.89
31 Determinants of compliance with anti-vectorial protective measures among non-immune travellers during missions to tropical Africa. Malar J 2011 0.87
32 Malaria Hyperendemicity and Risk for Artemisinin Resistance among Illegal Gold Miners, French Guiana. Emerg Infect Dis 2016 0.86
33 Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. Malar J 2013 0.84
34 Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast. Malar J 2012 0.83
35 In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na+/H+ exchanger transporter (Pfnhe-1) gene in 393 isolates from Dakar, Senegal. Malar J 2013 0.82
36 Anopheles salivary gland proteomes from major malaria vectors. BMC Genomics 2012 0.80
37 Plasmodium falciparum with multidrug resistance 1 gene duplications, Senegal. Emerg Infect Dis 2013 0.76
38 [Antiparasitic vaccines: where are we now?]. Rev Prat 2007 0.75
39 Zika Virus Persistence and Higher Viral Loads in Cutaneous Capillaries Than in Venous Blood. Emerg Infect Dis 2017 0.75
40 Expression and biochemical characterization of the Plasmodium falciparum protein kinase A catalytic subunit. Parasitol Res 2009 0.75